COSMOS Pharmaceutical (3349) Q3 2025 earnings summary

Executive summary

• Net sales for the nine months ended February 28, 2025, rose 5.2% year-over-year to ¥752,268 million, with operating profit up 33.2% and profit attributable to owners of parent up 28.7%.

• 81 new stores were opened across multiple regions, bringing the total to 1,570 stores at period end.

Financial highlights

• Operating profit reached ¥31,627 million, up 33.2% year-over-year; ordinary profit was ¥33,771 million, up 30.3%.

• Profit attributable to owners of parent was ¥22,343 million, a 28.7% increase year-over-year.

• Basic earnings per share for the period was ¥281.91, reflecting a 2-for-1 stock split.

• Comprehensive income for the period was ¥22,335 million, up 28.7% year-over-year.

Outlook and guidance

• Full-year net sales forecast is ¥1,037,000 million, up 7.5% year-over-year; operating profit forecast is ¥31,600 million, up 0.3%.

• Profit attributable to owners of parent is forecast at ¥24,500 million, with basic EPS of ¥309.12.

• No change to the previously released financial results forecast.